Ginkgo supplement suppresses steroid-induced ocular hypertension

Article

Gingko biloba extract (GBE) has an application in preventing steroid-induced ocular hypertension, according to study results published in the December issue of the Archives of Ophthalmology.

Gingko biloba extract (GBE) has an application in preventing steroid-induced ocular hypertension, according to study results published in the December issue of the Archives of Ophthalmology.

Li-Yun Jia, PhD of the Department of Ophthalmology and Visual Sciences, Chinese University of Hong Kong, Hong Kong and colleagues treated rabbits four times daily with topical TobraDEX (Alcon) and/or GBE 5 µg for 14 days. Intraocular pressure (IOP) was measured at three day intervals; the trabecular meshwork and extracellular matrix were enucleated, and cellularity and deposition graded.

GBE suppressed IOP increases caused by steroid application, and improved the cellularity of the trabecular meshwork. Applying GBE to cultured human trabecular meshwork cells inhibited the effects of the steroid: GBE attenuated apoptosis induced by anti-Fas ligands, reduced expression of myocilin and modulated the expression of stress-related genes heat-shock proteins 70 and 90, as well as the expression of B-crystallin.

As GBE proved a safe and effective means of preventing steroid-induced ocular hypertension in both an animal model and in human cells in vivo, the researchers concluded that this herbal compound could potentially be used as a dietary supplement used to prevent this type of hypertension.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.